CCCC — C4 Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $123.55m
- -$121.35m
- $35.58m
Annual income statement for C4 Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 33.2 | 45.8 | 31.1 | 20.8 | 35.6 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 93.6 | 128 | 161 | 160 | 155 |
| Operating Profit | -60.4 | -82.1 | -130 | -140 | -120 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -67 | -83.9 | -128 | -131 | -105 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -66.3 | -83.9 | -128 | -132 | -105 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -66.3 | -83.9 | -128 | -132 | -105 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -66.3 | -83.9 | -128 | -132 | -105 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.54 | -1.82 | -2.62 | -2.66 | -1.5 |
| Dividends per Share |